The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients

One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-03, Vol.14 (6), p.1569
Main Authors: Derebas, Justyna, Panuciak, Kinga, Margas, Mikołaj, Zawitkowska, Joanna, Lejman, Monika
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Blood diseases
Cancer therapies
Cell cycle
Cell therapy
Chemotherapy
Children
Chimeric antigen receptors
Cytotoxicity
Deoxyribonucleic acid
DNA
Drug dosages
FDA approval
Gene amplification
Hematological diseases
Immune system
Immunosuppressive agents
Immunotherapy
Lymphocytes T
Lymphoma
Medical prognosis
Monoclonal antibodies
Mortality
Non-Hodgkin's lymphoma
Patients
Pediatrics
Radiation
Review
Stem cell transplantation
T cell receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14061569